RxDoctor Payments Data

Gina Burge, NP

Family · Jackson, MSNPI 1184879439

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $194,911 of the $236,635 with a category attached, or 82.4%. AbbVie accounts for 76.7% of it on its own, with 52 other manufacturers making up the rest. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$236,635in general payments, 2019–2025

Across 1,295 payments — averaging $182.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$182K
  • Pfizer$30K
  • Biohaven Pharmaceutical Holding Company Ltd.$11K
  • Teva Pharmaceuticals USA, Inc.$1K
  • SK Life Science, Inc.$1K
  • Amgen$1K
  • plus $11K from 47 others

What the payments were for

  • Consulting fees$1,3711%
  • Speaking & faculty fees$194,91182%
  • Travel & lodging$15,5977%
  • Food & beverage$24,49010%
  • Education$2660%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$236,635 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$30,445
Medicare patients
198
Services billed
557

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate88$175,896
Aimovig AutoinjectorErenumab-Aooe145$113,604
UbrelvyUbrogepant51$81,772
Emgality PenGalcanezumab-Gnlm95$76,732
XcopriCenobamate23$29,113
BotoxOnabotulinumtoxina21$25,304
QuliptaAtogepant12$16,067
AptiomEslicarbazepine Acetate11$13,425
Pregabalin92$6,971
Topiramate ErTopiramate12$6,192
Levetiracetam122$4,231
Divalproex Sodium ErDivalproex Sodium135$3,088
Propranolol Hcl ErPropranolol Hcl81$2,749
Lacosamide35$2,617
Gabapentin140$2,254

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$29,623$175,89688 claims
AbbVieUbrelvy, Botox, Qulipta$181,523$123,14484 claims
SK Life Science, Inc.Xcopri$1,200$29,11323 claims
Sunovion Pharmaceuticals Inc.Aptiom$33$13,42511 claims
Upsher-smith Laboratories LLCTopiramate$149$2,078182 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.

Other family in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →